Jounce Therapeutics
A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Merger | |
| Total Funding | 000k | ||
Casdin Capital(exited)
Foresite Capital(exited)
Omega Funds(exited)
Wellington Management(exited)
Nextech Invest(exited)
Redmile Group(exited)
Cormorant Asset Management(exited)
Inbio Ventures(exited)
Pharmstandard(exited)
Third Rock Ventures(exited)
Redx(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (9 %) | 127 % | (58 %) | (57 %) | 205 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (21 %) | (42 %) | 38 % | (67 %) | (328 %) | (61 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (23 %) | (42 %) | 38 % | (70 %) | (338 %) | (62 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 95 % | 107 % | 45 % | 126 % | 331 % | 126 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Jounce Therapeutics
Edit
ACQUISITION by Jazz Pharmaceuticals Jul 2019